The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium

Journal of Medical Economics

Volumn 16, Issue 4, 2013, Pages 539-546

  Body, Jean Jacques ^a   Chevalier, Pierre ^b   Gunther, Oliver ^c   Hechmati, Guy ^d   Lamotte, Mark ^b  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b IQVIA   (United States)

^c AMGEN LTD   (United Kingdom)

^d AMGEN INC   (United States)

Author keywords

Bone metastasis; Cost; Retrospective; Skeletal related event; Solid tumor; SRE

Indexed keywords

ADULT; AMBULATORY CARE; ARTICLE; BELGIUM; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOPEDIC SURGERY; OUTPATIENT CARE; PATHOLOGIC FRACTURE; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RETROSPECTIVE STUDY; SOLID TUMOR; SPINAL CORD COMPRESSION; SPINE FRACTURE;

BELGIUM; BONE DISEASES; BONE NEOPLASMS; BREAST NEOPLASMS; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; FRACTURES, SPONTANEOUS; HEALTH EXPENDITURES; HUMANS; LUNG NEOPLASMS; MALE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RETROSPECTIVE STUDIES; SPINAL CORD COMPRESSION;

EID: 84875744941     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.774279     Document Type: Article

References (26)

1. Capanna R, Coia LR, Coleman R, et al. editors. Textbook of Bone Metastases. Hoboken, NJ: John Wiley and Sons; 2005. p 105
2. Rubens RD, Coleman RE. Bone metastases. In: Abeloff MD, Armitage JO, Lichter AS, et al., editors. Clinical oncology. New York: Churchill Livingstone; 1995. p 643-65
3. Crump M, Gluck S, Tu D, et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol 2008;26:37-43
4. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s.
5. Sugiura H, Sugiura T, Mitsudomi T. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 2008;466:729-36
6. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87
7. Henry D, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32
8. Stopeck AT, Lipton A, Body J-J, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9
9. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22
10. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-90
11. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst 2004;96:879-82
12. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602
13. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21
14. Hoefeler H, Duran I, Hechmati G, et al. Health resource utilization associated with skeletal-related events by tumour type in patients with bone metastases/lesions: European analysis of a prospective multinational observational study. Poster presented at European Multidisciplinary Cancer Congress (ECCO); Stockholm, September 2011
15. Hechmati G, Cure S, Goué po A, et al. Cost of skeletal-related events in patients with bone metastases to solid tumours based on the health resource utilization collected in a prospective European multinational observational study. Value in Health 2011;14:455
16. Gunther O, Body J-J, Sleeboom H, et al. Cost of skeletal complications from bone metastases: results from a retrospective European study. Support Care Cancer 2012;20(Suppl 1):S372
17. Gerlier L, De Vos C, Lamotte M, et al. Epidemiology of idiopathic thrombocytopenic purpura in Belgium assessed using Hospital records. ISPOR 11th Annual European Congress, Athens, 10-12 November 2008
18. Spaepen E, Demarteau N, Van Belle S, et al. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals. Oncologist 2008;13:596-607
19. Spaepen E, Merchant S, Neslusan C, et al. Costs and outcomes of nosocomial pneumonia in a sample of Belgian hospitals. ISPOR 9th Annual European Congress, Copenhagen, 28-31 October 2006
20. Annemans L, Rémy V, Lamure E, et al. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium. J Med Econ 2008;11:135-50
21. SPF Santé Publique. Cellule Technique de traitement de donné es relatives aux hô pitaux. Banque Nationale de Donné es Diagnostic mé dical/soins et cout. 2011. https://tct.fgov.be/webetct/ etct-web/html/fr/index.jsp (Accessed 3 July 2012)
22. Cleemput I, Van Wilder P, Vrijens F et al. Richtlijnen voor farmacoeconomische evaluaties in België. Health Technology Assessment (HTA). Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE); 2008. KCE Reports 78A (D/2008/10.273/23)
23. Powell C. The Delphi technique: myths and realities. J Adv Nursing 2003;41:376-82
24. Barlev A, Song X, Ivanov B, et al. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010;16:693-702
25. UK Government National Archives. Department of Health. Payment by Results (PbR) in 2008-09. http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/ Managingyourorganisation/Financeandplanning/NHSF inancialReforms/DH-081238 (Accessed 3 July 2012)
26. World Health Organization. CHOosing Interventions that are Cost-Effective (WHO-CHOICE). http://www.who.int/choice/country/deu/cost/en/(Accessed 3 July 2012)